InGeneron

InGeneron believes that evidence-based regenerative therapy will redefine the health care experience. Founded in 2006, we are a clinical-stage biotechnology company formed to innovate cell-based technologies for the next generation of regenerative medicine. InGeneron has always been a science-first company and we promise to always operate this way, even when it would be easier not to. InGeneron is currently pursuing FDA approval to ensure its Transpose® RT cell therapy platform is safe and effective. Our products have been available in Europe since 2014. InGeneron products carry CE marks and complies with all applicable health, safety, and environmental protections that are required at the time of manufacturing and that conform to the standards of European Union regulations. InGeneron’s cell therapy platform aims to provide novel, safe, evidence-based cell therapies using a patient’s own regenerative cells by rapidly and efficiently isolating a patient’s ADRC from their own adipose tissue for same day treatment. InGeneron’s Transpose® RT cell therapy platform enables physicians to isolate stem and regenerative cells from a patient’s own adipose tissue at point-of-care for same-day treatment.